The Paris Life Sciences team advised Bpifrance, through its InnoBio 2 and Large Venture funds, on the €96 million Series C financing of ImCheck Therapeutics, a French biotech company designing and developing a new generation of immunotherapy antibodies.
The round was co-led by two new investors, Earlybird and Andera Partners, and joined by Invus and le Leukemia & Lymphoma Society Therapy Acceleration Program®.
Existing investors including Bpifrance, the Growth Opportunity Fund of founding investor Kurma Partners, Eurazeo, Gimv, EQT Life Sciences (formerly LSP), Boehringer Ingelheim Venture Fund, Pfizer Ventures, Wellington Partners, Agent Capital, Pureos Bioventures and Alexandria Venture Investments participated.
The Goodwin team was led by Anne-Charlotte Rivière and included Johann Gandilhon on corporate aspects.